NASDAQ · BMEAHealthcarePharmaceuticals

Biomea Fusion financials

$1.26−2.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Gross margin—————
Operating income-$83.5M-$144.1M-$126.1M-$83.6M-$41.7M
Net income-$61.8M-$138.4M-$117.3M-$81.8M-$41.6M
Net margin—————
Diluted EPS$-1.18$-3.83$-3.44$-2.80$-1.74
EBITDA-$79.9M-$142.3M-$124.6M-$82.9M-$41.4M
Operating cash flow-$70.4M-$119.9M-$96.6M-$62.4M-$35.4M
Free cash flow-$70.4M-$120.3M-$100.0M-$63.4M-$38.6M
Diluted shares52.2M36.1M34.1M29.3M23.9M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$55.8M$58.3M$176.9M$111.9M$145.7M
Short-term investments$0.00$0.00$0.00$1.1M$27.8M
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$58.6M$79.9M$199.9M$129.3M$185.7M
Total liabilities$29.0M$28.4M$30.7M$20.8M$6.9M
Shareholders' equity$29.6M$51.6M$169.2M$108.5M$178.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology